Skip to main content

Table 4 Spearman correlation analyses between PCSK9 and platelet reactivity parameters according to diabetes status and P2Y12 inhibitor stratification

From: Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes

 

Whole cohort (n = 1027)

DM (n = 277)

Non-DM (n = 750)

r

P

r

P

r

P

Ticagrelor

n = 563

 

n = 143

 

n = 420

 

 MPA at 7 days

0.144

0.012

0.236

0.041

0.111

0.094

 MAADP at 7 days

0.080

0.228

0.336

0.013

0.033

0.664

Clopidogrel

n = 464

 

n = 134

 

n = 330

 

 MPA at 7 days

0.100

0.113

− 0.078

0.586

0.190

0.110

 MAADP at 7 days

− 0.048

0.546

− 0.172

0.160

− 0.041

0.667

  1. PCSK9 proprotein convertase subtilisin/kexin type 9, DM diabetes mellitus, Non-DM non-diabetes mellitus, MPA maximal platelet aggregation, MAADP maximum amplitude of adenosine diphosphate-induced platelet-fibrin clots